Surviving Lymphoma: Post-Cancer Fatigue

Fatigue is a lack of energy or weakness that differs from drowsiness. Fatigue will not go away with extra rest because it is usually the result of an underlying medical condition or treatment.

Cancer treatments like chemotherapy and radiation are known causes of fatigue. Because they are harsh on the body, your organs and cells need time to recover. Thus, fatigue makes you want to rest so you body can heal. However, this type of fatigue does not last too long and is perfectly normal.

Fatigue that continues on for a while may be the result of low blood counts leading to anemia. It's also possible that your thyroid was damaged during treatment. The thyroid helps with energy levels, so damage can result in fatigue. These and other causes are easily treatable, so talk to your doctor if you feel tired for an extended period of time post-treatment.

Post-Cancer Fatigue

Fatigue that persists after cancer is in remission and your medical team rules out other treatable causes is called Post-Cancer Fatigue (PCF).

Though there is no known cause for PCF, you shouldn't worry, as it's normal. Your doctor should continue your regular check-ups to ensure everything is ok.

Fatigue can make it hard to function on a day-to-day basis. The best thing to do is to get adequate rest and think about your energy level. Prioritize your daily tasks so you use your energy on the most important ones. "Establish a new normal" by adjusting your schedule to match your energy.

Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap